Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...
Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Thursday
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.
Piper Sandler Sticks to Its Buy Rating for Gilead Sciences (GILD)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Exelixis (EXEL) Receives a Buy from Piper Sandler
In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Exelixis (EXEL – Research Report), with a price ...
kalkinemedia1d
How Has Nurix Therapeutics (NASDAQ:NRIX) Performed Amid Market Volatility
Highlights,Sumitomo Mitsui Trust Group Inc. increased its holdings in Nurix Therapeutics by 42.7% in Q4.,Various firms have ...
Metastatic Colorectal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
pharmaphorum3d
BMS extends its position in ADCs with $180m Orum deal
This is the second partnership involving drugs combining ADC and protein degrader technologies in the last few weeks, coming after Seagen formed a wide-ranging partnership with Nurix with a top ...
manilatimes17h
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
Eran Ovadya, Chief Financial Officer of NurExone stated, "The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.